{"id":"azd0486","safety":{"commonSideEffects":[{"rate":null,"effect":"Stomatitis"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL6068301","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AZD0486 binds to and inhibits mTORC1, a key signaling complex that regulates cell growth, metabolism, and survival. By blocking mTORC1 activity, the drug reduces protein synthesis and induces cell cycle arrest, leading to reduced proliferation of cancer cells. This mechanism is particularly relevant in tumors with dysregulated mTOR pathway signaling.","oneSentence":"AZD0486 is a selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) that suppresses protein synthesis and cell proliferation in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:08.655Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors with mTOR pathway activation"}]},"trialDetails":[{"nctId":"NCT07215585","phase":"PHASE3","title":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-11","conditions":"Large B-cell Lymphoma","enrollment":420},{"nctId":"NCT06549595","phase":"PHASE3","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-07","conditions":"Untreated Follicular Lymphoma","enrollment":1018},{"nctId":"NCT04594642","phase":"PHASE1","title":"A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-03-02","conditions":"B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma","enrollment":317},{"nctId":"NCT06526793","phase":"PHASE2","title":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-11-27","conditions":"B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)","enrollment":240},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT06137118","phase":"PHASE1, PHASE2","title":"AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-29","conditions":"B-cell Acute Lymphoblastic Leukemia (B-ALL)","enrollment":163}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TNB-486","Surovatamig"],"phase":"phase_3","status":"active","brandName":"AZD0486","genericName":"AZD0486","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD0486 is a selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) that suppresses protein synthesis and cell proliferation in cancer cells. Used for Advanced or metastatic solid tumors with mTOR pathway activation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}